CING S-3/A SEC Filing Analysis

Latest settled — T+20d

CING ▼ -15.44% at T+20d

SHORT call ✓ call won +15.44% · α vs SPY +22.86% · entry $6.93 → $5.86

Next anchor: T+60d in 26d

Currently $4.65 · +32.90% from $6.93 entry (call sign-flipped)

Entry anchored
Mar 20, 03:58 PM ET
via Databento tick

T+1d

-3.17%

call +3.17% · α +2.82%

$6.71

settled 8w ago

T+5d

-15.73%

call +15.73% · α +12.16%

$5.84

settled 8w ago

T+20d

-15.44%

call +15.44% · α +22.86%

$5.86

settled 4w ago

T+60d

—

call — · α —

—

in 26d

Price Chart

Loading chart...

Executive Summary

Cingulate Inc. filed an S-3/A amendment solely to update the auditor's consent from KPMG LLP. The filing does not modify the prospectus or indicate new securities issuance. However, the company's financials show a deteriorating position with declining cash, recurring losses, and reliance on dilutive financing, raising going concern doubts.

Actionable Insight

Avoid equity investment due to extreme dilution risk and going concern issues. Monitor FDA decision on CTx-1301 in May 2026, but company likely needs emergency financing before then which could wipe out current shareholders.

Key Facts

S-3/A filing is purely administrative, updating KPMG's consent without changing the prospectus
Company has $0 market cap and CINGW is likely delisted or non-trading
Cash dropped from $12.2M to $6.1M in 9 months while net loss was $16.2M
Relies on continuous dilutive financing (ATM, Lincoln Park, debt conversions)
Management turmoil: CEO on administrative leave due to domestic battery charge
FDA approval of lead drug CTx-1301 expected May 2026, but company may not survive until then

Financial Impact

Continuing cash burn of ~$1.8M/month with $6.1M remaining; needs $9M more to reach PDUFA date

cashequitydilution

Risk Factors

Insufficient cash to continue operations beyond mid-2026
Extreme shareholder dilution from continuous ATM and Lincoln Park financings
Management instability with CEO on leave
No revenue and complete dependence on FDA approval for survival

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
S-3/A Filing (Primary)	0001493152-26-012075
Exhibit: ex23-1.htm	0001493152-26-012075
Document: 0001493152-26-012075-index-headers.html	0001493152-26-012075
Document: 0001493152-26-012075-index.html	0001493152-26-012075
Document: 0001493152-26-012075.txt	0001493152-26-012075
CONTEXT: 10-Q (2025-11-13)	0001493152-25-022395

4 reports for CING

T+1T+5T+20T+60

Filters

Reports for CING — sortable, filterable
	Type				Now
Mar 25, 2026 8w ago	EFFECT NEUTRAL ★ 4/10	$6.36 $5.62	▼ −11.64%	▼ −19.50%	$4.65 (−26.89%)
Mar 23, 2026 8w ago	S-3/A BEARISH ★ 3/10	$6.93 $5.86	▲ +15.44%	▲ +22.86%	$4.65 (+32.90%)
Mar 18, 2026 9w ago	DEFA14A NEUTRAL ★ 3/10	$7.51 $5.45	▼ −27.43%	▼ −35.05%	$4.65 (−38.08%)
Mar 18, 2026 9w ago	8-K NEUTRAL ★ 4/10	$8.04 $5.26	▼ −34.58%	▼ −40.62%	$4.65 (−42.16%)

US Market Status

Market Open — Closes in 4h 14m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access